Atossa Genetics - Endoxifen catalysts expected in 2019
Atossa Genetics’ endoxifen programs are awaiting key catalysts in the coming year. Top-line data from a Phase II study in women with elevated mammographic breast density (MBD) is expected in Q219. The high rate of dropouts due to skin irritation/rashes may prompt a formulation change. The firm is also advancing an oral endoxifen formulation to reduce cancer cell activity in the window of opportunity between breast cancer diagnosis and surgery, and in women refractory to tamoxifen. Our rNPV-derived equity valuation is $37.3m, or $3.81 per fully diluted share, up from $3.66/share previously.Atossa Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. The company's primary program is the development of Endoxifen, which is an active metabolite of tamoxifen to treat and prevent breast cancer. The company is developing an oral and topical form of Endoxifen. The company's Endoxifen is being developed to potentially treat a number of conditions, including: mammographic breast density; breast cancer in the window of opportunity between diagnosis of breast cancer and surgery; gynecomastia, which is male breast enlargement; and the recurrence of breast cancer.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.